Innocoll to Report Second Quarter 2015 Financial Results and Host Webcast and Conference Call on August 14, 2015
07. August 2015 08:00 ET
|
Innocoll Holdings plc
ATHLONE, Ireland, Aug. 7, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) (the "Company"), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of...
Innocoll AG Appoints Jose Carmona as Chief Financial Officer
01. Juli 2015 07:00 ET
|
Innocoll Holdings plc
Appointment is effective on September 1, 2015
Gordon Dunn will continue as Vice President, Finance Director, Europe
ATHLONE, Ireland, July 1, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL)...
Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation for Cogenzia for the Adjunctive Treatment of Moderate and Severe Diabetic Foot Infection
30. Juni 2015 07:00 ET
|
Innocoll Holdings plc
ATHLONE, Ireland, June 30, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
Innocoll AG to Present at JMP Securities Healthcare Conference
17. Juni 2015 16:05 ET
|
Innocoll Holdings plc
ATHLONE, Ireland, June 17, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-2 Phase 3 Study for the Treatment of Diabetic Foot Infection
15. Juni 2015 07:00 ET
|
Innocoll Holdings plc
ATHLONE, Ireland, June 15, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-1 Phase 3 Study for the Treatment of Diabetic Foot Infection
15. Mai 2015 07:00 ET
|
Innocoll Holdings plc
ATHLONE, Ireland, May 15, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
Innocoll AG Announces First Quarter Financial and Operating Results
14. Mai 2015 07:00 ET
|
Innocoll Holdings plc
ATHLONE, Ireland, May 14, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of...
Innocoll to Report First Quarter 2015 Financial Results and Host Webcast and Conference Call on May 14, 2015
07. Mai 2015 16:30 ET
|
Innocoll Holdings plc
ATHLONE, Ireland, May 7, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) (the "Company"), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of...
Innocoll AG Announces Pricing of Follow-On Offering
24. April 2015 08:00 ET
|
Innocoll Holdings plc
ATHLONE, Ireland, April 24, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a specialty pharmaceutical company, today announced the pricing of its follow-on public offering of 3,321,669 American...
Pivotal Pharmacokinetic Study of Innocoll's XaraColl(R) Supports Use of 300 mg Dose for Phase 3 Clinical Studies in Post-Operative Pain
01. April 2015 07:00 ET
|
Innocoll Holdings plc
ATHLONE, Ireland, April 1, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical...